1、Designation: D4774 111Standard Specification forUser Applied Drug Labels in Anesthesiology1This standard is issued under the fixed designation D4774; the number immediately following the designation indicates the year oforiginal adoption or, in the case of revision, the year of last revision. A numb
2、er in parentheses indicates the year of last reapproval. Asuperscript epsilon () indicates an editorial change since the last revision or reapproval.1NOTEFigures 1-6 were corrected editorially in April 2012.1. Scope1.1 This specification covers the size, color, pattern, andtype used on labels applie
3、d to unlabeled syringes filled by theusers or their agents to identify the drug content. This speci-fication is not intended to cover labels applied by the drugmanufacturer.1.2 The values stated in SI units are to be regarded as therecommended values. The use of inch-pound system values,not being ex
4、act equivalents, may result in nonconformancewith the standard.1.3 This standard does not purport to address all of thesafety concerns, if any, associated with its use. It is theresponsibility of the user of this standard to establish appro-priate safety and health practices and determine the applic
5、a-bility of regulatory limitations prior to use.2. Referenced Documents2.1 ASTM Standards:2D996 Terminology of Packaging and Distribution Environ-ments2.2 Other Standard:Pantone Matching System33. Terminology3.1 DefinitionsGeneral definitions for packaging and dis-tribution environments are found in
6、 Terminology D996.4. Size and Background Color Requirements4.1 Label SizeThe labels shall have a nominal length of25 to 35 mm and a width of 10 to 13 mm.4.2 Label Background ColorThe colors and patternsgiven in Fig. 1 shall be used to distinguish these groups ofdrugs. The background color shall not
7、interfere with the abilityof the user to write information on the label.4.2.1 AntagonistsTo denote an antagonist, 1-mm widediagonal stripes of the agonist color alternating with a 1-mmwide white stripe shall be used. The stripes shall run from thelower left to the upper right at an angle of approxim
8、ately 45to the long axis of the label. The name of an antagonist drugshall appear in the center of the label and the striping shall beomitted behind and below the name (see Fig. 2).1This specification is under the jurisdiction of ASTM Committee D10 onPackaging and is the direct responsibility of Sub
9、committee D10.32 on Consumer,Pharmaceutical and Medical Packaging.Current edition approved April 1, 2011. Published May 2011. Originallyapproved in 1988. Last previous edition approved in 2006 as D4774 06. DOI:10.1520/D4774-11E01.2For referenced ASTM standards, visit the ASTM website, www.astm.org,
10、orcontact ASTM Customer Service at serviceastm.org. For Annual Book of ASTMStandards volume information, refer to the standards Document Summary page onthe ASTM website.3Available from Pantone, Inc., 509 Commerce Boulevard, Carlstadt, NJ070723098.1Copyright ASTM International, 100 Barr Harbor Drive,
11、 PO Box C700, West Conshohocken, PA 19428-2959, United States.5. Significance and Use5.1 The objective of this specification is to facilitate iden-tification of drugs in syringes filled by the user. The use ofcolors is intended only as an aid in identification of drug groupsand does not absolve the
12、user from the duty to read the label tocorrectly identify the drug prior to use.5.2 The user may alternatively use black and white labelsrather than these colored labels.FIG. 1 Standard Background Colors for User Applied Syringe Drug LabelsFIG. 2 Label for an Antagonist DrugD4774 11126. Type and Col
13、or Requirements6.1 The type should be as large as possible (minimum10-point) using bold type. Upper and lower case letters arepreferred for better legibility.All printing shall be in black boldwith the exception of “SUCCINYLCHOLINE, “EPINEPH-RINE and Beta Blockers “ESMOLOL”, METOPROLOL”,“LABATOLOL”
14、which shall be printed against the backgroundcolor as bold reverse plate letters within a black bar (copper barfor Beta Blockers) running from edge to edge on the upper halfof the label, the rest of which shall display the coloredbackground (see Fig. 3).6.1.1 The established (generic) name of the dr
15、ug shall beused. The use of the proprietary (trade) name of the drug isoptional. The initial syllable, or initial two syllables, of thedrug name may be emphasized by being printed in a bold uppercase type a minimum of 2 points larger than the remainder ofthe drug name, which is typed in lower case (
16、see Fig. 4).6.1.2 Except for antagonists, the name of the drug andconcentration (for example, “mg/mL,” “meq/mL,” or “mcg/mL”; see Fig. 3 and Fig. 5) should be printed on the upper halfof the label to leave space below for entry of the date, time, andinitials of user).6.1.3 For induction agents and l
17、ocal anesthetics the concen-tration of the solution (as “% or “mg/mL) and the date ofpreparation should appear on the label, as shown in Fig. 6.6.1.4 For antagonists the name of the drug should be printedalong the center line of the label to permit a sufficient width ofdiagonal stripes to appear abo
18、ve the name for easy recognition(see Fig. 2).7. Keywords7.1 anesthesiology; drug labels; label requirementsASTM International takes no position respecting the validity of any patent rights asserted in connection with any item mentionedin this standard. Users of this standard are expressly advised th
19、at determination of the validity of any such patent rights, and the riskof infringement of such rights, are entirely their own responsibility.This standard is subject to revision at any time by the responsible technical committee and must be reviewed every five years andif not revised, either reappr
20、oved or withdrawn. Your comments are invited either for revision of this standard or for additional standardsand should be addressed to ASTM International Headquarters. Your comments will receive careful consideration at a meeting of theresponsible technical committee, which you may attend. If you f
21、eel that your comments have not received a fair hearing you shouldmake your views known to the ASTM Committee on Standards, at the address shown below.This standard is copyrighted by ASTM International, 100 Barr Harbor Drive, PO Box C700, West Conshohocken, PA 19428-2959,United States. Individual re
22、prints (single or multiple copies) of this standard may be obtained by contacting ASTM at the aboveaddress or at 610-832-9585 (phone), 610-832-9555 (fax), or serviceastm.org (e-mail); or through the ASTM website(www.astm.org). Permission rights to photocopy the standard may also be secured from the
23、ASTM website (www.astm.org/COPYRIGHT/).FIG. 3 Reversed Plate Printing Used to Identify(SUCCINYLcholine,(EPINEPHrine,( and Beta Blockers,(ESMOlol,(LABATolol,( and (METOprolol(NOTEBold upper-case type is shown for first or first and second syllables of the drug name.FIG. 4 Optional PrintingFIG. 5 Drug Name and DosageFIG. 6 Alternative Label Showing Concentration in Percent and mg/mLD4774 1113
